Antibody conjugate therapeutics: challenges and potential.
about
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaLinkers Having a Crucial Role in Antibody-Drug ConjugatesAntibody-drug conjugates--an emerging class of cancer treatmentProgress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery SystemsAntibody-drug conjugates as novel anti-cancer chemotherapeuticsThe development of immunoconjugates for targeted cancer therapyTargeting CD19 in B-cell lymphoma: emerging role of SAR3419Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewOvercoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancerAn integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.Anti-CD37 antibodies for chronic lymphocytic leukemia.Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.High efficiency diffusion molecular retention tumor targeting.Principles and application of antibody libraries for infectious diseases.Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotoxSelective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) LigandThe development of potential antibody-based therapies for myelomaSpatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian CancerTherapeutic antibodies against cancer.N-Sulfonyl-β-lactam hapten as an effective labeling reagent for aldolase mAb.Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.Introduction to monoclonal antibodies.A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.Computational selection of antibody-drug conjugate targets for breast cancer.Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancerAntibody-based therapeutics for the treatment of human B cell malignanciesDesign, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumorsAntibody-drug conjugates: Intellectual property considerations.Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenograftsAnti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers.Methods for site-specific drug conjugation to antibodies.Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma.Advances in the treatment of hematologic malignancies using immunoconjugatesAntibody therapy for pediatric leukemia.Antibody-drug conjugates - a perfect synergy.
P2860
Q24633761-A3FCA37D-FE77-47F2-807D-AC6C6535DD05Q26752763-CD8FE1D9-D32F-450A-A9AB-C9A6F7B1DE53Q26770312-768469FD-112F-4017-963A-9E62DFFCFC01Q26782485-8B39C9C3-060C-4053-AEFE-961FABAA0340Q26800175-509D61EB-48FC-4B01-A0F6-F8FE92F57F9CQ27021990-0CCFB5A8-BD35-4ECF-9A03-8CCD1EBEF1CCQ27027562-E8E7E469-6526-4C81-A8F3-A0E859DEBD73Q27304386-8B704E5F-58EA-44B4-8087-B35971E05E41Q30544833-B1918B97-945F-46F9-AADE-5940F2E2886DQ30980266-4A4F628C-F3C7-4A09-B509-2AF1E60638DEQ33689021-DE384FE2-021A-4E55-9E0F-4BD7A83C7321Q33926952-33CE747D-72EE-4D4A-AD2E-96B3C8E1813EQ34405641-95048E8A-85D3-46BC-8D3B-6D152C9F3567Q34486159-4D8B8050-24AF-4543-A2FA-219F00AD74EFQ34625694-E5C01631-E13B-41A4-A880-0DBAC5AAD320Q35249355-3331F236-4A7E-4F26-847F-DA92243F1D9CQ35446035-40D356F5-D110-455D-8AFC-B7F3C49F550CQ35652998-179B5C6C-6A50-45CF-A079-8ABB1A2D8D9FQ35788245-92E79B42-E431-4F84-8FF9-66C2B33FD606Q35882323-A7A79A00-E533-4C70-816F-F88277A9C188Q35908498-27BF363D-625F-4AA2-89A5-4C21B32C8E61Q35924212-863FE42D-74E7-46E0-BB37-230EF032946AQ35992503-186C71BF-8DC0-46A5-995A-DC5E55E5B988Q36050008-EF8D5909-F231-4FDC-A259-632A48FF3435Q36285117-050C44E0-62CD-498D-9FA9-4E1FA42DE08CQ36752488-3DAA9292-1E61-41E2-AB7B-70B6AC4E8C5FQ36771856-90599CB9-3716-44BB-86CF-EF106F85E075Q36824455-5452D62D-67C7-4B8F-B9C1-05ABC148AF29Q36907540-1A5E5CEF-F6B7-43DD-ABD8-E1EE9D5CA3F7Q36907976-667347CC-3BC1-466B-BB7C-5B501BDA2958Q37138213-5308FEBC-7F92-4A58-9620-37A0ED38FA81Q37175328-678A3543-11EF-4175-A9B7-A5EC50AD0B36Q37257515-FDAB45D5-6D0E-4FDA-9CDC-80702DA56762Q37536570-79E4F299-6B85-44F1-81EB-5F4864994CA6Q37593707-F91A294C-120B-477E-A894-CF6CE56E0975Q37628646-EFA0373B-30CD-4146-8483-4AAB4803E35EQ37632992-7EB4701F-EB5E-4334-B45E-FC945085A1CDQ37697843-641D9334-5289-4975-AFD3-643EF10DBC63Q37725578-8057CC25-3B98-4AED-96E5-C3E0985D1792Q38014923-7EA254B6-C461-4531-B291-0503A3A2F38B
P2860
Antibody conjugate therapeutics: challenges and potential.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antibody conjugate therapeutics: challenges and potential.
@ast
Antibody conjugate therapeutics: challenges and potential.
@en
Antibody conjugate therapeutics: challenges and potential.
@nl
type
label
Antibody conjugate therapeutics: challenges and potential.
@ast
Antibody conjugate therapeutics: challenges and potential.
@en
Antibody conjugate therapeutics: challenges and potential.
@nl
prefLabel
Antibody conjugate therapeutics: challenges and potential.
@ast
Antibody conjugate therapeutics: challenges and potential.
@en
Antibody conjugate therapeutics: challenges and potential.
@nl
P1476
Antibody conjugate therapeutics: challenges and potential.
@en
P2093
Beverly A Teicher
Ravi V J Chari
P304
P356
10.1158/1078-0432.CCR-11-1417
P407
P577
2011-10-01T00:00:00Z